Clover Health Investments Corp (NASDAQ: CLOV)’s stock price has plunge by 1.17relation to previous closing price of 3.43. Nevertheless, the company has seen a 4.52% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-22 that Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders’ Meeting Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders’ Meeting
Is It Worth Investing in Clover Health Investments Corp (NASDAQ: CLOV) Right Now?
Company’s 36-month beta value is 2.00.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLOV is 383.22M, and currently, short sellers hold a 3.23% ratio of that floaft. The average trading volume of CLOV on April 29, 2025 was 5.83M shares.
CLOV’s Market Performance
CLOV’s stock has seen a 4.52% increase for the week, with a -6.22% drop in the past month and a -24.73% fall in the past quarter. The volatility ratio for the week is 3.08%, and the volatility levels for the past 30 days are at 6.00% for Clover Health Investments Corp The simple moving average for the last 20 days is -1.52% for CLOV stock, with a simple moving average of 2.96% for the last 200 days.
Analysts’ Opinion of CLOV
Many brokerage firms have already submitted their reports for CLOV stocks, with Craig Hallum repeating the rating for CLOV by listing it as a “Buy.” The predicted price for CLOV in the upcoming period, according to Craig Hallum is $6 based on the research report published on December 17, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see CLOV reach a price target of $4. The rating they have provided for CLOV stocks is “Neutral” according to the report published on October 07th, 2024.
Cowen gave a rating of “Market Perform” to CLOV, setting the target price at $3 in the report published on February 02nd of the previous year.
CLOV Trading at -7.22% from the 50-Day Moving Average
After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.75% of loss for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 3.08%, as shares sank -3.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.57% lower at present.
During the last 5 trading sessions, CLOV rose by +4.52%, which changed the moving average for the period of 200-days by +158.96% in comparison to the 20-day moving average, which settled at $3.52. In addition, Clover Health Investments Corp saw 10.16% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLOV starting from Edwards Carladenise Armbrister, who sale 200,000 shares at the price of $3.61 back on Mar 07 ’25. After this action, Edwards Carladenise Armbrister now owns 273,227 shares of Clover Health Investments Corp, valued at $722,000 using the latest closing price.
Priest Brady Patrick, the CEO of Home Care of Clover Health Investments Corp, sale 75,000 shares at $3.68 during a trade that took place back on Mar 06 ’25, which means that Priest Brady Patrick is holding 2,418,151 shares at $276,000 based on the most recent closing price.
Stock Fundamentals for CLOV
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.27 for the gross margin
The net margin for Clover Health Investments Corp stands at -0.03. The total capital return value is set at -0.12. Equity return is now at value -14.75, with -8.04 for asset returns.
Currently, EBITDA for the company is -44.94 million with net debt to EBITDA at 4.41. When we switch over and look at the enterprise to sales, we see a ratio of 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
In a nutshell, Clover Health Investments Corp (CLOV) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
